SCHEMBL29619012

SCHEMBL29619012

COCCNCCOc1ccc(NC(=O)C2CC2)cc1-c1c(C)noc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA5 P31644 1/20 0.41
MAPT P10636 3/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HTR2A P28223 3/20 0.41
KDM4E B2RXH2 1/20 0.41
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
POLB P06746 1/20 0.39
HTR2C P28335 1/20 0.39
CYP1A2 P05177 1/20 0.39
ALOX15 P16050 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CREBBP Q92793 1/20 0.39
PDE5A O76074 1/20 0.39
ABL1 P00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31677953 0.88 KDM4E (0.43) MAPTSMN1; SMN2HTR2AKDM4EPOLB
SCHEMBL29619091 0.88 GABRA5 (0.46) GABRA5MAPTLMNASMN1; SMN2HTR2A
SCHEMBL29619109 0.87 MAPT (0.44) GABRA5MAPTLMNASMN1; SMN2HTR2A
SCHEMBL29619210 0.86 GABRA5 (0.41) GABRA5MAPTLMNASMN1; SMN2HTR2A
SCHEMBL29619113 0.85 MET (0.43) MAPTLMNAHTR2AKDM4ECYP3A4
SCHEMBL24398567 0.84 POLB (0.52) MAPTLMNASMN1; SMN2CYP3A4CYP2C9
SCHEMBL29619040 0.83 HTR2A (0.46) GABRA5MAPTLMNASMN1; SMN2HTR2A
SCHEMBL29619009 0.83 GABRA5 (0.41) GABRA5MAPTLMNASMN1; SMN2HTR2A
SCHEMBL29619101 0.83 HTR2A (0.49) HTR2AHTR2C
SCHEMBL29619051 0.83 HTR2A (0.51) HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376090-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2024-11-14 US disclosed
EP-4236942-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2023-09-06 EP disclosed
WO-2022093850-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376090-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO HTR2A, HTR5A, HTR1A GABRA5 40/4885MAPT 1759/4885LMNA 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.